Note issued by a good analyst (which of course eliminates Suraj in my personal opinion). Note from Craig Hallum about the call yesterday. Says company is seeing sales pick up nicely and expects March to be a record revenue month. CH "expects the rapid adoption to continue as the market is educated on the clinical benefits of MDXG's wound care portfolio." CH also expects the FDA will finalize the study protocols by June. MDXG ended FY with 76 reps, added 34 by February conf call and will exit Q1 with 120 sales reps with a target of 130-150 by year end. "We believe this is a testament to Management's confidence in the continued adoption of its products as the year progresses and into 2015." CH also discusses that MDXG calmed the fears of some investors by laying out reimbursement scenarios beg in 2015. Closes with the stock opportunity stating that "the valuation does not fully reflect the inherent value of its product portfolio given that MiMedx is at the front end of a significant growth ramp as it penetrates a large and very lucrative market.. ..reiterate our buy rating and $10 price target...6.5X our FY15 revenue estimate...We believe this premium multiple is warranted given the company's significant growth rate, superior management team, wide competitive moat and advantageous reimbursement environment."